Literature DB >> 18068525

FAS -1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer.

Sokbom Kang1, Seung Myung Dong, Sang Soo Seo, Jae Weon Kim, Sang Yoon Park.   

Abstract

Single-nucleotide polymorphisms of the FAS -1377G/A, FAS -670A/G, and FASL -844T/C genes may alter transcriptional activity of these genes. Recent evidence suggests an association of these polymorphisms with an increased risk of cervical cancer, so we explored this relationship. Genotypes of 155 patients with cervical cancer and 160 healthy control subjects were determined using polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP). Associations with cancer risk were estimated using two-sided logistic regression. We observed a significantly increased risk of lymph node metastasis associated with the FAS -1377 GA or AA polymorphism [odds ratio (OR) = 4.16, 95% confidence interval (CI) = 1.10 to 15.74; P = 0.036]. In addition, the FAS -670AG or GG genotype showed an increased incidence of node metastasis, but these findings were not statistically significant (OR = 3.67, 95% CI = 0.96-14.00, P = 0.059). There was no significant association between an increased risk of cervical cancer and polymorphisms of the death pathway genes FAS and FASL. None of the polymorphisms were associated with risk of advanced stage or histologic subtype of cervical cancer. In conclusion, FAS -1377 G-->A polymorphism may be associated with an increased risk of lymph node metastasis in Korean cervical cancer patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18068525     DOI: 10.1016/j.cancergencyto.2007.09.002

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  29 in total

1.  Polymorphisms of the FAS and FASL genes and risk of breast cancer.

Authors:  Wenmin Wang; Zhongqiu Zheng; Wenjie Yu; Hui Lin; Binbin Cui; Feilin Cao
Journal:  Oncol Lett       Date:  2011-12-28       Impact factor: 2.967

2.  FAS -1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls.

Authors:  Li-Xin Qiu; Jian Shi; Hui Yuan; Xin Jiang; Kai Xue; Hai-Feng Pan; Jin Li; Ming-Hua Zheng
Journal:  Hum Genet       Date:  2009-02-19       Impact factor: 4.132

3.  Association between FAS A670G polymorphism and susceptibility to cervical cancer: evidence from a meta-analysis.

Authors:  Jian Shen; Ning-Xia Sun
Journal:  Tumour Biol       Date:  2013-07-31

4.  CD95 rs1800682 polymorphism and cervical cancer risk: evidence from a meta-analysis.

Authors:  Yan Zhang; Shengchun Tong; Lihua Guan; Fei Na; Wei Zhao; Li Wei
Journal:  Tumour Biol       Date:  2013-10-11

5.  Genetic association between CD95 rs2234767 polymorphism and cervical cancer risk: a meta analysis.

Authors:  Ping Liu; Zibai Wei; Xiaofeng He; Junyan Yu; Xiangyang Tian; Jianlan Chang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

6.  Significant association among the Fas -670 A/G (rs1800682) polymorphism and esophageal cancer, hepatocellular carcinoma, and prostate cancer susceptibility: a meta-analysis.

Authors:  Tao Liu; Li Zuo; Lin Li; Lei Yin; Kai Liang; Hongyuan Yu; Hui Ren; Wen Zhou; Hongwei Jing; Yang Liu; Chuize Kong
Journal:  Tumour Biol       Date:  2014-08-02

7.  Letter regarding Wang GQ et al. entitled "associations between Fas/FasL polymorphisms and susceptibility to cervical cancer: a meta-analysis".

Authors:  Ying Zeng; Jia Liu; Jinjin Yan; Hui Liu; Shuhua Xiong
Journal:  Tumour Biol       Date:  2014-07-04

8.  Association between CD95L polymorphism and cervical cancer risk: evidence from a meta-analysis.

Authors:  Jing Zhu; Lei Lu; Xiang Cheng; Rongkai Xie; Zhengqiong Chen; Youfei Li; Guilan Lin; Jianmei Liu; Ying Yang
Journal:  Tumour Biol       Date:  2014-03-12

9.  Lack of association between the FAS/FASL polymorphisms and cervical cancer risk: A meta-analysis.

Authors:  Yingying DU; Lixia Hu; Yueyin Pan
Journal:  Biomed Rep       Date:  2013-01-17

10.  FAS and FAS-L genotype and expression in patients with recurrent pregnancy loss.

Authors:  Priscilla Chamelete Andrade Banzato; Silvia Daher; Evelyn Traina; Maria Regina Torloni; Bárbara Yasmin Gueuvoghlanian-Silva; Renata Fiorini Puccini; Karen Priscilla Tezotto Pendeloski; Rosiane Mattar
Journal:  Reprod Sci       Date:  2013-02-18       Impact factor: 3.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.